In the catchment area of the DIST, the investigators estimate that there are approximately 600 professional FSWs. Overall, the investigators are expecting to reach approximately 500 FSWs and to recruit and follow-up at least 90% of the HIV-positive (n~100) and at least 60% of the HIV-negative under PreP (n~250). Women eligible to ART under current guidelines and asymptomatic women with CD4 >350 cells/mm³ (TasP component) will be offered locally approved first line ART regimens while HIV-negative ones (PrEP component) will receive Truvada®. For all the analyses on TasP, the investigators will compare the women enrolled under the TasP component to those treated based on current national guidelines. Pregnant women and those still breastfeeding will be excluded from the PrEP component of the project. Women eligible to ART under current guidelines will receive their drugs through the NACP program, while those on TasP or PrEP will be supplied in drugs by this project.